Press Releases

Oct 05, 2017

Jun 15, 2017

ProBioGen grants a license for human lymph node technology to TissUse for Multi-Organ-Chip applications

Jun 01, 2016

Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology

May 18, 2016

ProBioGen Will License GlymaxX® to Thermo Fisher Scientific for Use in Developing Allergy Diagnostics

Apr 19, 2016

ProBioGen And Eucodis Sign Agreement to Commercialize C-LiNK, A Novel Antibody Drug Conjugation Technology

Oct 28, 2015

ProBioGen in Biosimilar Deal with Bio Farma Indonesia

Oct 14, 2015

Zymeworks Contracts ProBioGen for Bi-specific GlymaxX® Antibody Cell Line Development

Oct 01, 2015

ProBioGen Inks Another Commercial GlymaxX® License and Contract Manufacturing Service Agreement on Immuno-Oncology Antibody

Jun 02, 2015

Anti-Ebola MVA Vaccine Produced on ProBioGen’s Avian AGE1.CR® Cell Line Platform in Clinical Trials

Sep 09, 2014

20 Years ProBioGen: Invests €20 million in Mammalian Manufacturing Expansion

Page 7 of 11

Press Releases

Chiome Bioscience Selects ProBioGen for GlymaxX® Antibody Manufacturing Program

ProBioGen grants a license for human lymph node technology to TissUse for Multi-Organ-Chip applications

Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology

ProBioGen Will License GlymaxX® to Thermo Fisher Scientific for Use in Developing Allergy Diagnostics

ProBioGen And Eucodis Sign Agreement to Commercialize C-LiNK, A Novel Antibody Drug Conjugation Technology

ProBioGen in Biosimilar Deal with Bio Farma Indonesia

Zymeworks Contracts ProBioGen for Bi-specific GlymaxX® Antibody Cell Line Development

ProBioGen Inks Another Commercial GlymaxX® License and Contract Manufacturing Service Agreement on Immuno-Oncology Antibody

Anti-Ebola MVA Vaccine Produced on ProBioGen’s Avian AGE1.CR® Cell Line Platform in Clinical Trials

20 Years ProBioGen: Invests €20 million in Mammalian Manufacturing Expansion